Firm-Wide blog

Valsartan Recall Continues to Expand and FDA Addresses Cancer Risk

By Burg Simpson
August 21, 2018
2 min read

On August 20, FDA announced that yet another manufacturer of Valsartan-containing products, Torrent Pharmaceuticals Limited, was recalling certain lots of its drugs following FDA testing that revealed contamination with NDMA – a known cancer causing agent.

View the Expanded Recall Announcement Here

Torrent Pharmaceuticals’s Valsartan products can now be counted among the more than 50 Valsartan-containing drugs pulled from the market since mid-July due to their contamination with NDMA.

While the FDA’s investigation continues, it has made it known that the levels of NDMA in the recalled products is not trivial. According to FDA, 96 nanograms of NDMA per day is a reasonably safe amount for humans to ingest. If a person consumed this amount every day for their lifetime, it is estimated that their risk of developing cancer from this exposure would be less than 1 in 100,000.  This risk of developing cancer rises to 1 in 8,000, however, for those who ingested 320 mg of contaminated Valsartan for four years. As stated by FDA, “This assessment led to FDA’s decision to have these batches recalled.”

If you or a loved one have taken Valsartan and have had liver, bladder, or kidney cancer or disease, contact one the dangerous drug attorneys at Burg Simpson today to discuss your legal rights. Call us at 1-800-713-9340 or fill out our contact form here for a FREE no-obligation consultation today.

Free case evaluation form